Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial

BACKGROUND: Patients with B cell malignancies refractory to allogeneic stem cell transplantation (SCT) can be treated by subsequent immunotherapy with donor lymphocyte infusions (DLI). But unlike myeloid leukemia, B cell leukemia and lymphoma are less sensitive to allogeneic adoptive immunotherapy....

Descripción completa

Detalles Bibliográficos
Autores principales: Buhmann, Raymund, Michael, Stanglmaier, Juergen, Hess, Horst, Lindhofer, Peschel, Christian, Kolb, Hans-Jochem
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3702397/
https://www.ncbi.nlm.nih.gov/pubmed/23815981
http://dx.doi.org/10.1186/1479-5876-11-160

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3702397/
https://www.ncbi.nlm.nih.gov/pubmed/23815981
http://dx.doi.org/10.1186/1479-5876-11-160

Ejemplares similares